All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Psoriasis and Psoriatic Arthritis Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Adalimumab-adaz HCF receives U.S. FDA approval

Mar 22, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in psoriasis.

The U.S. Food and Drug Administration (FDA) has granted approval to biosimilar adalimumab-adaz high concentration formula (HCF).1

Adalimumab-adaz has been approved for seven indications, aligned with its reference drug adalimumab, including psoriatic arthritis and plaque psoriasis.1

Adalimumab, the active component in adalimumab-adaz, is an inhibitor of tumor necrosis factor (TNF), which is commonly overproduced in autoimmune disorders such as psoriatic arthritis and plaque psoriasis. The overproduction of TNF can result in symptoms such as joint, skin, and mucosal inflammation.1

The U.S. FDA have approved adalimumab-adaz following the results of the phase I pharmacokinetics bridging study which compared adalimumab (50 mg/mL) with adalimumab-adaz (100 mg/mL). The trial met all primary endpoints and adalimumab-adaz was found to have comparable safety, pharmacokinetics, and immunogenicity.1

  1. Novartis. Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation. Published Mar 21, 2023. Accessed Mar 22, 2023.


Subscribe to get the best content related to psoriasis and psoriatic arthritis delivered to your inbox